Jnana Therapeutics Patent US12595244B2 - SLC6A19 Inhibitors

ChangeBridge: Patent Grants - Pharma (A61K)

Published April 7th, 2026

Detected April 7th, 2026

Summary

The USPTO granted Patent US12595244B2 to Jnana Therapeutics Inc. on April 7, 2026, covering small molecule compounds that inhibit mammalian SLC6A19 function. The patent protects 2 claims relating to compositions useful for treating diseases associated with abnormal amino acid levels. The invention spans multiple CPC classifications in heterocyclic compound chemistry.

View original document View source feed page

What changed

USPTO granted Patent US12595244B2 to Jnana Therapeutics covering small molecule inhibitors of SLC6A19, a sodium-dependent amino acid transporter. The patent includes claims to compounds within specific heterocyclic structural families (piperidines, pyridines, pyrimidines) and methods of using these compounds to treat amino acid-related diseases or disorders.

Pharmaceutical and biotechnology companies developing treatments targeting amino acid absorption or metabolism should review this patent for potential licensing needs or design-around strategies. The patent's broad coverage of SLC6A19 modulation could affect freedom-to-operate analyses for kidney disease, metabolic disorders, or intestinal absorption programs involving this transporter.

What to do next

Review patent claims for potential licensing or work-around strategies if developing amino acid transport modulators
Monitor for continuation applications or divisional patents from the same family
Assess freedom-to-operate implications for SLC6A19-related therapeutic programs

Source document (simplified)

← USPTO Patent Grants

Small molecule inhibitors of mammalian SLC6A19 function

Grant US12595244B2 Kind: B2 Apr 07, 2026

Assignee

Jnana Therapeutics Inc.

Inventors

Dean G. Brown, Giovanni Muncipinto, Joshua Ethan Zweig, Long Vo Nguyen

Abstract

Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A19 transport.

CPC Classifications

A61K 31/4523 A61K 31/4525 A61K 31/453 A61K 31/4535 A61K 31/454 A61K 31/4545 A61K 31/497 A61K 31/501 A61K 31/506 A61K 31/5377 C07D 211/58 C07D 401/06 C07D 401/04 C07D 401/14 C07D 403/04 C07D 405/06 C07D 405/14 C07D 409/06 C07D 409/14 C07D 413/04 C07D 413/06 C07D 413/12 C07D 413/14 C07D 417/04 C07D 417/06 C07D 417/14 C07D 471/04 C07D 487/04